Replies to post #126887 on Biotech Values

[DewDiligence]

I don’t think anyone cares whether you or zipjet were closer in your share-price prediction. The pertinent point for investors is that MNTA’s enterprise value (market cap less net cash) is now only $250M on a fully-diluted basis.

If anyone can find another company with a $250M enterprise value that has better prospects than MNTA, I’d like to know about it.

[Rocky3]

I thought valuation and where a stock traded were the same thing. And I guess to be technical you can say that tL still wasn't approved, so it's still undecided what valuation MNTA will trade for post the event.

LOL.

Well, my price guess was more than where MNTA was trading at the time, so I think that it was clear that I was talking about intrinsic value not where it would trade at any specific point. Plus I commented that I thought that it could trade at cash after approval of a generic competitor.

The issue is whether the market will ever recognize the value that I see. As always, I'm sufficiently stupid to think that I know more than the market. Like most, I am usually wrong on that issue. But being right a couple times in a lifetime can make up for all the errors plus plus.